ArticleCureus2026
Primary Signet-Ring Cell Adenocarcinoma of the Urinary Bladder: A Report of a Rare Case.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary signet-ring cell carcinoma (PSRCC) of the urinary bladder is a rare histological variant and is often diagnosed at an advanced stage. Here we are reporting a case of a 48-year-old male who presented to us with painless hematuria, which was associated with increased frequency of urination and a sensation of incomplete bladder emptying. On diagnostic evaluation, it was confirmed as PSRCC of the urinary bladder. The patient underwent radical cystectomy in view of recurrent disease and subsequently received radiation therapy with concurrent cisplatin. Follow-up after completion of treatment revealed the development of skeletal and penile metastases. The patient is currently 12 months post chemoradiation and was started on chemotherapy. This case highlights the aggressive clinical course of this rare malignancy and emphasizes the multimodality management and close follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.